Evaluation of Ameliorative Effect of Quercetin and Candesartan in Doxorubicin-Induced Cardiotoxicity

Investigating the cardioprotective potential of quercetin against tacrolimus-induced cardiotoxicity in Wistar rats: A mechanistic insights

Purpose

The aim of this research study is to assess the ability of quercetin to protect the heart from the negative consequences of tacrolimus-induced cardiotoxicity.

Methods

A total of 30 rats were divided into 5 groups. Tacrolimus was used to induce cardiotoxicity, whereas quercetin was employed as a protective agent.

Results

Tacrolimus administration significantly raised the levels of serum cardiac biomarkers (Lactate dehydrogenase, creatine kinase-myocardial band, and troponin-I) as well as inflammatory biomarkers (tumor necrosis alpha and interleukin 6). The administration of quercetin reduced raised levels of cardiac and inflammatory biomarkers significantly. In addition, treatment with tacrolimus resulted in higher malondialdehyde (MDA) (lipid peroxidation marker) levels and falling in the levels of reduced glutathione (GSH) as well as antioxidant enzymes such as superoxide dismutase (SOD), glutathione reductase (GR), and catalase (CAT). Quercetin treatment significantly reduced MDA levels and increased GSH and antioxidant enzyme (SOD, GR, and CAT) levels. Moreover, the tacrolimus-administered group exhibited histological changes in cardiac tissue cited as vacuole formation, large and uncondensed nucleus, and cardiomyocyte hypertrophy. The quercetin treatment reduced the inflammatory cell infiltration in cardiac tissue and thus reduced vacuole formation and hypertrophy.

Conclusions

The outcome showed quercetin's cardioprotective potential against tacrolimus-administered cardiotoxicity. Consequently, it is concluded that quercetin may be used as add-on therapy with tacrolimus to reduce cardiac adverse effects.

Mitigating Doxorubicin-Induced Cardiotoxicity through Quercetin Intervention: An Experimental Study in Rats

Doxorubicin (DOX) is an effective anticancer drug, but its use is limited by dose-dependent heart toxicity. Quercetin is a natural antioxidant frequently studied for its beneficial properties. Moreover, a wide range of dietary supplements are available for human use. This in vivo study aimed to explore the potential cardioprotective effects of quercetin in chronic DOX treatment. A total of 32 Wistar rats were randomly divided into four groups: control, DOX, DOX/Q-50, and DOX/Q-100, treated with saline, 2.5 mg/kg body-weight DOX, 2.5 mg/kg body-weight DOX + 50 mg quercetin, and 2.5 mg/kg body-weight DOX + 100 mg quercetin, respectively, for two weeks. Rats were monitored using cardiac ultrasound (US) and markers for cardiac injury. Oxidative damage and ultrastructural changes in the heart were investigated. Chronic DOX treatment led to a decline in cardiac function and elevated values of NT pro-BNP, troponin I, and CK-MB. Quercetin treatment slightly improved certain US parameters, and normalized serum NT pro-BNP levels. Furthermore, DOX-induced SOD1 depletion with consequent Nrf2 activation and DNA damage as shown by an increase in γH2AX and 8HOdG. Quercetin treatment alleviated these alterations. Oral administration of quercetin alleviated serum markers associated with DOX-induced cardiotoxicity. Furthermore, it exhibited a favorable impact on the cardiac US parameters. This suggests that quercetin may have potential cardioprotective properties.

A Comparative Study of Tumor-Specificity and Neurotoxicity between 3-Styrylchromones and Anti-Cancer Drugs

Background. Many anti-cancer drugs used in clinical practice cause adverse events such as oral mucositis, neurotoxicity, and extravascular leakage. We have reported that two 3-styrylchromone derivatives, 7-methoxy-3-[(1E)-2-phenylethenyl]-4H-1-benzopyran-4-one (Compound A) and 3-[(1E)-2-(4-hydroxyphenyl)ethenyl]-7-methoxy-4H-1-benzopyran-4-one (Compound B), showed the highest tumor-specificity against human oral squamous cell carcinoma (OSCC) cell lines among 291 related compounds. After confirming their superiority by comparing their tumor specificity with newly synthesized 65 derivatives, we investigated the neurotoxicity of these compounds in comparison with four popular anti-cancer drugs. Methods: Tumor-specificity (TS_M, TS_E, TS_N) was evaluated as the ratio of mean CC₅₀ for human normal oral mesenchymal (gingival fibroblast, pulp cell), oral epithelial cells (gingival epithelial progenitor), and neuronal cells (PC-12, SH-SY5Y, LY-PPB6, differentiated PC-12) to OSCC cells (Ca9-22, HSC-2), respectively. Results: Compounds A and B showed one order of magnitude higher TS_M than newly synthesized derivatives, confirming its prominent tumor-specificity. Docetaxel showed one order of magnitude higher TS_M, but two orders of magnitude lower TS_E than Compounds A and B. Compounds A and B showed higher TS_M, TS_E, and TS_N values than doxorubicin, 5-FU, and cisplatin, damaging OSCC cells at concentrations that do not affect the viability of normal epithelial and neuronal cells. QSAR prediction based on the Tox21 database suggested that Compounds A and B may inhibit the signaling pathway of estrogen-related receptors.